Collaboration with AstraZeneca will focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic ...

To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.

Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.

Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...

Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA's open ...

“Historically, cell and gene therapy manufacturing has been manual, almost artisanal," says Fred Parietti, CEO of Multiply Labs. "Expert scientists perform hundreds of tasks by hand, from pipetting to ...